Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline
Cet article présente les recommandations de l'"American Society of Clinical Oncology" et du "Cancer Care Ontario" concernant le traitement systémique d'un cancer du poumon à petites cellules
PURPOSE : To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer.
METHODS : An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.
RESULTS : The literature search identified 95 relevant studies to inform the evidence base for this guideline.
RECOMMENDATIONS : Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance status, role of biomarkers, and use of myeloid-supporting agents in patients with small-cell lung cancer.
Journal of Clinical Oncology , article en libre accès, 2022